Trastuzumab deruxtecan

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 抗体、酶促裂解的肽接头、拓扑异构酶 I 抑制剂 (毒素成分 Dxd) 组成。Trastuzumab deruxtecan 可用于 HER2 阳性乳腺癌和胃癌的研究。

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.

——

——

——

Others

Other Targets

Antibody-Drug Conjugates (ADCs)

——

——

1826843-81-5

Approximately 45.42 kDa

——

>98% (HPLC)

In Vitro:? H2O 中的溶解度 : 10 mg/mL (超声加热助溶)

——

——

(-20℃)

With Ice Pack

≥ 2 years